Skip to main content
. 2021 Jan 19;2(1):100184. doi: 10.1016/j.xcrm.2020.100184

Figure 3.

Figure 3

BBB permeability affects the efficacy of treatment against intracranial Mel57 tumors

(A) Efficacy of paclitaxel against intracranial Mel57 tumors grafted in WT or Abcb1a/b−/− mice. Data are represented as means ± SEs (n ≥ 6).

(B) Efficacy of docetaxel against intracranial Mel57 tumors grafted in WT or Abcb1a/b−/− mice. Data are represented as means ± SEs (n ≥ 8).

(C) Efficacy of docetaxel against intracranial Mel57VEGF tumors grafted in WT or Abcb1a/b−/− mice. Data are represented as means ± SEs (n ≥ 7); ∗p < 0.05.

(D) Efficacy of docetaxel against Mel57 tumors grafted in the renal subcapsule of WT mice. Data are represented as means ± SEs (n ≥ 5); ∗∗p < 0.01.

In all of the panels, arrows indicate the days of taxane administration.